Heron Therapeutics Announces Data on SUSTOL™ Program to be Presented at 2014 ASCO Annual Meeting
05/19/2014
|
Presentation details are as follows:
Poster Title: | Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy (Abstract #9645) | ||
Session Title: | Patient and Survivor Care – General Poster Session | ||
Author/Presenter: | Ralph V. Boccia, MD, FACP, Founder, Center for Cancer and Blood Disorders, Bethesda, MD | ||
Poster Number: | 295 | ||
Date/Time: | Sunday, June 1, 2014 from 8:00 a.m. – 11:45 a.m. CDT | ||
Poster Title: | A prospective, randomized, double-blind phase 3 trial of extended-release granisetron (APF530) vs palonosetron (PALO) for preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately (MEC) or highly (HEC) emetogenic chemotherapy: does a reanalysis using newer ASCO emetogenicity criteria affect study conclusions? (Abstract #9648) | ||
Session Title: | Patient and Survivor Care – General Poster Session | ||
Author/Presenter: | Harry Raftopoulos, MD, Associate Professor, Hofstra North Shore-LIJ School of Medicine | ||
Poster Number: |
298 |
||
Date/Time: | Sunday, June 1, 2014 from 8:00 a.m. – 11:45 a.m. CDT |
About SUSTOL™
Heron's lead product candidate, SUSTOL™ (granisetron), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV in patients receiving moderately emetogenic chemotherapy (MEC); none are approved for delayed-onset CINV in patients receiving highly emetogenic chemotherapy (HEC). SUSTOL contains the 5-HT3 receptor antagonist granisetron formulated in the Company's proprietary Biochronomer™ polymer-based drug delivery platform, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. Currently available intravenous and oral formulations of granisetron are approved only for the prevention of acute-onset CINV. Granisetron was selected for SUSTOL because it is widely prescribed by physicians based on a well-established record of safety and efficacy.
About
Forward Looking Statements
This news release contains "forward-looking statements" as defined by
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements involve risks and uncertainties, including
uncertainties associated with the potential approval of SUSTOL™
and the potential timing for such approval, if approved at all; risks
relating to progress in research and development of HTX-011, including
the timing of planned toxicology and clinical studies; risks related to
other programs; risks related to the launch and acceptance of new
products and other risks and uncertainties identified in the Company's
filings with the
Source:
Heron Therapeutics, Inc
Investor Relations Contact:
Jennifer
Capuzelo, 858-703-6063
jcapuzelo@herontx.com
and
Corporate
Contact:
Stephen R. Davis, 650-366-2626
Executive Vice
President and Chief Operating Officer